Healthcare Industry News: amyotrophic lateral sclerosis
News Release - January 13, 2010
FDA Gives TCA Cellular Therapy Green Light to Proceed with First ALS Adult Stem Cell Trial Using Patient's Own Stem CellsCOVINGTON, La.--(HSMN NewsFeed)--TCA Cellular Therapy, LLC (TCA-CT) announced today that the U.S. Food and Drug Administration (FDA) has approved its adult stem cell protocol to conduct Phase I clinical trials to treat amyotrophic lateral sclerosis (ALS or Lou Gehrigís disease).
This is the second FDA-approved protocol for the treatment of ALS using stem cells in the country; and the first using adult stem cells from the same patient. The aim of the Phase I study will assess safety.
ALS afflicts approximately 30,000 Americans. More people die of ALS than Huntingtonís disease; and the fatalities nearly equal Multiple Sclerosis. The life expectancy of a patient diagnosed with ALS is two to five years.
ďI hope that our trial, along with the combined efforts of scientists and patients, will pave the way to breaking the chains of this devastating disease,Ē stated Gabriel Lasala, M.D., president and CEO of TCA Cellular Therapy.
About the Trial
Under the scientific guidance of cellular biologist, Jose J. Minguell, Ph.D., the adult stem cells will be taken from the patientís bone marrow in a simple outpatient procedure. The cells will then be processed in TCA-CTís GMP laboratory and administered to the patient by spinal tap in one of TCA-CTís facilities.
Recruitment for trial patients will commence in the next few weeks. The company anticipates moving into Phase II within a year.
About TCA Cellular Therapy
TCA Cellular Therapy, a privately-held company located in Covington, Louisiana, has assembled a team of neurologists, neurosurgeons, cell biologists, and pathologists to study some of the most debilitating neurological diseases including ALS and Spinal Cord Injuries.
Source: TCA Cellular Therapy
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.